Detalhe da pesquisa
1.
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.
Nat Immunol
; 24(5): 792-801, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37081148
2.
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
Nature
; 625(7993): 166-174, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38057662
3.
Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells.
Nature
; 595(7868): 578-584, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34135508
4.
A conserved dendritic-cell regulatory program limits antitumour immunity.
Nature
; 580(7802): 257-262, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32269339
5.
Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunity.
Nature
; 582(7813): E17, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32499658
6.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol
; 80(3): 431-442, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37972660
7.
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.
J Vasc Interv Radiol
; 35(5): 722-730.e1, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38342221
8.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35313048
9.
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.
Liver Int
; 43(3): 695-707, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36577703
10.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int
; 42(11): 2538-2547, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35986902
11.
Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients.
J Vasc Interv Radiol
; 31(11): 1729-1738.e1, 2020 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-33012649
12.
Is There an Impact of Locoregional Therapy on Immune Response Modulation in HCC?
Radiology
; 303(1): 226-228, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35014907
13.
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
Hepatology
; 74(1): 483-490, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33369758
14.
Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody.
Ann Surg Oncol
; 29(1): 30-32, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34117573
15.
Optimizing care in early phase cancer trials: The role of palliative care.
Cancer Treat Rev
; 128: 102767, 2024 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-38776612
16.
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Nat Rev Clin Oncol
; 21(4): 294-311, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38424197
17.
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Nat Med
; 30(4): 1044-1053, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38584166
18.
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Cancer Lett
; 596: 217001, 2024 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38838764
19.
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
J Immunother Cancer
; 12(3)2024 Mar 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38448038
20.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol
; 19(6): 928-940, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38278303